Jagsonpal Pharmaceuticals Limited — PPTs, 26-07-2025: Investor Presentation

**1. Financial Highlights:**

Jagsonpal Pharma reported strong Q1FY26: Revenue soared 23.1% YoY to ₹75.6 Cr. Operating EBITDA jumped 24.1% to ₹15.7 Cr (20.8% margin). PAT more than doubled to ₹10.8 Cr (14.3% margin). Gross margins reached 64.4%. Cash balance is robust at ₹160.9 Cr.

**2. Strategic Initiatives & Growth Drivers:**

Growth is driven by disciplined execution and brand-building. Plans include deepening domestic market presence, launching 4-6 new products annually, and pursuing strategic inorganic opportunities for expansion.

**3. Business Developments:**

Jagsonpal strengthens its robust portfolio across Gynaecology, Orthopaedics, Dermatology, and Child-care. Many brands hold top market positions, supported by an efficient asset-light operating model.

**4. Market Position & Competitive Advantage:**

A therapy powerhouse, Jagsonpal ranks #7 in Gynae and #2 in Orthopaedics CVM. Its pan-India presence, strong brand equity, and lean operations offer a significant competitive advantage.

**5. Investor Implications:**

Strong Q1 results and robust cash signal positive growth potential. Jagsonpal's strategic focus on market expansion and inorganic growth could drive further value; execution will be key to monitor.